ClinicalTrials.gg
RecruitingNCT06078189TRAPEzEUpdated Sep 10, 2026

Rhizarthrosis Surgery and Functional Recovery: Arthroplasty vs. Trapezectomy

An observational study in Rhizarthrosis, sponsored by Clinique Bizet. Recruiting at 1 site in France. Open to participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Clinique Bizet · Observational

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Ages
45 Years to 85 Years
Sex
All
01

Study summary

Rhizarthrosis is a form of osteoarthritis that affects the trapeziometacarpal joint at the base of the thumb, which is more common in women over 50. Genetic and hormonal factors as well as the frequency of certain physical movements may contribute to its appearance. Surgical treatment is recommended if medical treatment fails, and trapezectomy is currently considered the standard method, although 3rd generation trapeziometacarpal prostheses are also available.

The aim of this study is to compare the clinical and radiographic results after surgical treatment of rhizarthrosis: prosthesis versus trapezectomy.

Read the detailed description

This is a two-center, randomized, prospective, comparative study.

The functional, clinical and radiographic evaluation in the early, medium and long term will make it possible to determine the possible superiority of arthroplasty if it exists.

The close evaluation of the patients during the first 3 months will make it possible to update the superiority of the arthroplasty on the functional recovery in the short term if it exists.

02

Conditions studied

  • Rhizarthrosis

Keywords

  • osteoarthritis - Trapezectomy
03

In context

Lead sponsor

Clinique Bizet is the lead sponsor of 16 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with symptomatic disabling osteoarthritis in failure of medical treatment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >45 years
  2. Symptomatic trapezius-metacarpal osteoarthritis after failure of medical treatment ( night orthosis 3 months + failure of 2 infiltrations/year)
  3. Patient who has given his/her consent to participate in the study after being informed by the surgeon,
  4. Patient living in France and able to answer the survey alone.
  5. Subject affiliated to a social security system or beneficiary of such a system
  6. No participation in any other clinical study

Exclusion criteria

Exclusion Criteria:

  1. Minor patient
  2. Trapezium height \< 8 mm
  3. Major subject protected by law, under curatorship or guardianship
  4. Known allergy to the materials of the medical device
  5. Local infection
  6. Local skin necrosis or unhealed wound
  7. Pregnant or nursing women
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Control

    Trapezectomy group

  • Experimental

    Arthroplasty group

    Device: HORUS

Interventions

  • DeviceHORUS

    The trapezium-metacarpal arthroplasty consists of the installation of a bipolar prosthesis composed of a metacarpal implant and a trapezial implant articulated through a metacarpal "head".

06

What researchers measure

Primary outcomes

  1. patient assessment of the wrist

    Quick-Dash score (11 minimum value and 55 is maximum )

    Time frame: 4 weeks

Secondary outcomes

  1. patient assessment of the wrist pain

    Visual Analogical Assessment score (0 no pain 10 severe pain)

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
  • Clinique BIZET
    Paris, 75116, France
    Recruiting
    • Bouchra BENKESSOU, MP · Contact0764486016
    • Camille ECHALIER, DR · Principal investigator
    • Jean- Noel GOUBIER, DR · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Dec 2027, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2023
First posted
Oct 11, 2023
StartActual
Nov 24, 2023
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06078189
Lead sponsor
Clinique Bizet
Responsible party
Sponsor
First posted
Oct 11, 2023
Start date
Nov 24, 2023
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 10, 2026

Study contacts

Bouchra BENKESSOU, PM
Contact
b.benkessou@hexagone-santé-paris.fr
0764486016

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion